Tamoxifen Pharmacogenetics in Asian Breast Cancer Women

Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376

NCT04961632 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients

NCT01169792 ·Status: COMPLETED

Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen

NCT00532454 ·Status: TERMINATED ·Phase: PHASE2

Effect of Pharmacogenomics Differences in Phase I and II Metabolism of Tamoxifen on Efficacy and Toxicity

NCT00886535 ·Status: COMPLETED

Genotyping and Phenotyping of CYP2D6 Breast Cancer Patients on Tamoxifen

NCT03504631 ·Status: UNKNOWN

The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer

NCT00830973 ·Status: COMPLETED

Tamoxifen in Treating Women With Breast Cancer

NCT00003678 ·Status: UNKNOWN ·Phase: PHASE3

Tamoxifen for the Prevention of Breast Cancer in High-Risk Women

NCT00002644 ·Status: COMPLETED ·Phase: PHASE3

Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer

NCT00096369 ·Status: TERMINATED ·Phase: PHASE2

Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of Tamoxifen

NCT03582865 ·Status: UNKNOWN

Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients

NCT03931928 ·Status: COMPLETED ·Phase: PHASE2

Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen

NCT00764322 ·Status: COMPLETED ·Phase: PHASE2

Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer

NCT00899197 ·Status: TERMINATED

Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients

NCT02132000 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels

NCT04312347 ·Status: COMPLETED ·Phase: NA

Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients

NCT01027416 ·Status: COMPLETED ·Phase: NA

Therapeutic Dose Monitoring (TDM) of Tamoxifen

NCT05133674 ·Status: UNKNOWN ·Phase: PHASE2

Study of Tamoxifen Dose Escalation in Breast Cancer Patients With CYP2D6 Polymorphisms

NCT01075802 ·Status: COMPLETED ·Phase: NA

A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer

NCT00001378 ·Status: COMPLETED ·Phase: PHASE1

PharmacoKINEtics of TAMoxifen and Its Metabolites in Breast Cancer Patients: the Influence of a Dose Increase in Phenotypic Poor Metabolizers of CYP2D6 (KINETAM)

NCT01192308 ·Status: COMPLETED ·Phase: PHASE1

Tamoxifen Pharmacogenetics and Clinical Effects

NCT00228930 ·Status: COMPLETED

Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up

NCT01357772 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors

NCT01196936 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）

NCT03137368 ·Status: UNKNOWN ·Phase: PHASE3

Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer

NCT00253539 ·Status: COMPLETED ·Phase: PHASE2